We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concordance of CSF measures of Alzheimer’s pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays.
- Authors
Keshavan, Ashvini; Wellington, Henrietta; Zhongbo Chen; Khatun, Ayesha; Chapman, Miles; Hart, Melanie; Cash, David M.; Coath, William; Parker, Thomas D.; Buchanan, Sarah M.; Keuss, Sarah E.; Harris, Matthew J.; Murray-Smith, Heidi; Heslegrave, Amanda; Fox, Nick C.; Zetterberg, Henrik; Schott, Jonathan M.
- Abstract
INTRODUCTION: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with presymptomatic Alzheimer’s disease (AD) pathology on amyloid positron emission tomography (PET). METHODS: In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (ttau), and phosphorylated tau at site 181 (p-tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter-platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut-points optimizing concordance with 18Fflorbetapir amyloid PET status (n = 63). RESULTS: Measurements of CSF Aβ, p-tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P < .0001); those of t-tau and t-tau/Aβ42 correlated moderately (r 0.57 to 0.79, P < .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut-points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 forMSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p-tau181. DISCUSSION: The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology.
- Subjects
CEREBROSPINAL fluid; AMYLOID beta-protein; TAU proteins; EMISSION-computed tomography; ALZHEIMER'S disease
- Publication
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021, Vol 13, Issue 1, p1
- ISSN
2352-8729
- Publication type
Article
- DOI
10.1002/dad2.12131